Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Barrett Esophagus 12Esophageal Neoplasms 9Colorectal Neoplasms 8Stomach Neoplasms 6Rectal Neoplasms 6Nasopharyngeal Carcinoma 6Colonic Neoplasms 5Adenocarcinoma Of Esophagus 5Gastroesophageal Reflux 4Squamous Cell Carcinoma of Head and Neck 3Pathologic Complete Response 3Neoplasms 3Carcinoma 3Lung Neoplasms 2Fistula 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms, Hereditary Nonpolyposis 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Upper Tract Urothelial Carcinoma 1Thyroid Neoplasms 1Stomach Ulcer 1Stomach Diseases 1Signs and Symptoms 1Sarcoma 1Recurrence 1Precancerous Conditions 1Polyposis, Gastric 1Peptic Ulcer 1Paranasal Sinus Neoplasms 1

Interventions

Cyclophosphamide 72fludarabine 65Tacrolimus 43fludarabine phosphate 40Whole-Body Irradiation 37Mycophenolic Acid 35Busulfan 32Melphalan 28Antilymphocyte Serum 23thymoglobulin 22Thiotepa 20Methotrexate 20Standard of Care 19Stem Cell Transplantation 17Practice Guidelines as Topic 17Granulocyte Colony-Stimulating Factor 17Rituximab 15Surveys and Questionnaires 12Sirolimus 12Filgrastim 12Interviews as Topic 11Cyclosporine 11Blood Specimen Collection 11Peripheral Blood Stem Cell Transplantation 10Exercise 10venetoclax 9Mesna 9Cytarabine 9Bortezomib 9Hematopoietic Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Neoplasms × Endoscopy × Clear all
NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡